E ric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently disclosed significant stock transactions. According to a Form 4 filing with the Securities and ...

SAN DIEGO—Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently disclosed stock transactions in a filing with the Securities and Exchange Commission.

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...

Neurocrine (NBIX) Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained effects of INGREZZA capsules on the physical, social and ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate. Analysts ...